AZT federal reimbursement
HHS and members of Congress are discussing additional funding sources to provide AZT to AIDS patients who lack other reimbursement plans, Secretary Bowen told a Sept. 15 briefing. HHS has reportedly talked with Sen. Weicker (R-Conn.). Bowen said he wants "not [to] make it an entitlement program" but simply extend funds for AZT therapy to states for six additional months to allow Congress and states more time to find reimbursement solutions. Congress appropriated $ 30 mil. to states last year in a block grant for AZT therapy. Only one state, California, and the District of Columbia have moved to replace the federal grant, Bowen pointed out. A House-Senate conference committee report on the 1989 HHS Appropriations Bill chides the congressional health committees and the states for not adopting measures to pay for AIDS drugs for patients who otherwise cannot afford to obtain them.
You may also be interested in...
Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-seven guidance documents have been posted on the tracker since its last update.
Despite a recent disappointment in a similar partnership with BioNTech, Genentech is pushing ahead with its neoantigen-targeting strategy.